First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.
Saved in:
| Title: | First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. |
|---|---|
| Authors: | Wermke M; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de.; National Center for Tumor Diseases, Dresden, Germany., Holderried TAW; Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany., Luke JJ; Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Morris VK; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA., Alsdorf WH; Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Wetzko K; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany., Andersson BS; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hossain MB; Immatics US, Inc, Houston, Texas, USA., Grund-Gröschke S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Aslan K; Immatics Biotechnologies GmbH, Tuebingen, Germany., Satelli A; Immatics US, Inc, Houston, Texas, USA., Marisetty A; Immatics US, Inc, Houston, Texas, USA., Satam S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Kalra M; Immatics US, Inc, Houston, Texas, USA., Hukelmann J; Immatics Biotechnologies GmbH, Tuebingen, Germany., Kursunel MA; Immatics Biotechnologies GmbH, Tuebingen, Germany., Pozo K; Immatics US, Inc, Houston, Texas, USA., Acs A; Immatics Biotechnologies GmbH, Tuebingen, Germany., Backert L; Immatics Biotechnologies GmbH, Tuebingen, Germany., Baumeister M; Immatics Biotechnologies GmbH, Tuebingen, Germany., Bunk S; Immatics Biotechnologies GmbH, Tuebingen, Germany., Wagner C; Immatics Biotechnologies GmbH, Tuebingen, Germany., Schoor O; Immatics Biotechnologies GmbH, Tuebingen, Germany., Mohamed AS; Immatics US, Inc, Houston, Texas, USA., Mayer-Mokler A; Immatics Biotechnologies GmbH, Tuebingen, Germany., Hilf N; Immatics Biotechnologies GmbH, Tuebingen, Germany., Krishna D; Immatics US, Inc, Houston, Texas, USA., Walter S; Immatics US, Inc, Houston, Texas, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Britten CM; Immatics Biotechnologies GmbH, Tuebingen, Germany. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 22; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 22. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39038917 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Wermke+M%22">Wermke M</searchLink>; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany Martin.Wermke@uniklinikum-dresden.de.; National Center for Tumor Diseases, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Holderried+TAW%22">Holderried TAW</searchLink>; Department of Hematology, Oncology, Immunooncology, Stem Cell Transplantation, and Rheumatology, University Hospital Bonn, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Luke+JJ%22">Luke JJ</searchLink>; Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Morris+VK%22">Morris VK</searchLink>; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center Division of Cancer Medicine, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Alsdorf+WH%22">Alsdorf WH</searchLink>; Department of Oncology, Hematology, and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Wetzko+K%22">Wetzko K</searchLink>; Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.<br /><searchLink fieldCode="AU" term="%22Andersson+BS%22">Andersson BS</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Wistuba+II%22">Wistuba II</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Parra+ER%22">Parra ER</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Hossain+MB%22">Hossain MB</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Grund-Gröschke+S%22">Grund-Gröschke S</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Aslan+K%22">Aslan K</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Satelli+A%22">Satelli A</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Marisetty+A%22">Marisetty A</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Satam+S%22">Satam S</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kalra+M%22">Kalra M</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Hukelmann+J%22">Hukelmann J</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Kursunel+MA%22">Kursunel MA</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Pozo+K%22">Pozo K</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Acs+A%22">Acs A</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Backert+L%22">Backert L</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Baumeister+M%22">Baumeister M</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Bunk+S%22">Bunk S</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Wagner+C%22">Wagner C</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Schoor+O%22">Schoor O</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Mohamed+AS%22">Mohamed AS</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Mayer-Mokler+A%22">Mayer-Mokler A</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Hilf+N%22">Hilf N</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany.<br /><searchLink fieldCode="AU" term="%22Krishna+D%22">Krishna D</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Walter+S%22">Walter S</searchLink>; Immatics US, Inc, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Britten+CM%22">Britten CM</searchLink>; Immatics Biotechnologies GmbH, Tuebingen, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2024 Jul 22; Vol. 12 (7). <i>Date of Electronic Publication: </i>2024 Jul 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39038917 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2023-008668 Languages: – Code: eng Text: English Titles: – TitleFull: First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Wermke M – PersonEntity: Name: NameFull: Holderried TAW – PersonEntity: Name: NameFull: Luke JJ – PersonEntity: Name: NameFull: Morris VK – PersonEntity: Name: NameFull: Alsdorf WH – PersonEntity: Name: NameFull: Wetzko K – PersonEntity: Name: NameFull: Andersson BS – PersonEntity: Name: NameFull: Wistuba II – PersonEntity: Name: NameFull: Parra ER – PersonEntity: Name: NameFull: Hossain MB – PersonEntity: Name: NameFull: Grund-Gröschke S – PersonEntity: Name: NameFull: Aslan K – PersonEntity: Name: NameFull: Satelli A – PersonEntity: Name: NameFull: Marisetty A – PersonEntity: Name: NameFull: Satam S – PersonEntity: Name: NameFull: Kalra M – PersonEntity: Name: NameFull: Hukelmann J – PersonEntity: Name: NameFull: Kursunel MA – PersonEntity: Name: NameFull: Pozo K – PersonEntity: Name: NameFull: Acs A – PersonEntity: Name: NameFull: Backert L – PersonEntity: Name: NameFull: Baumeister M – PersonEntity: Name: NameFull: Bunk S – PersonEntity: Name: NameFull: Wagner C – PersonEntity: Name: NameFull: Schoor O – PersonEntity: Name: NameFull: Mohamed AS – PersonEntity: Name: NameFull: Mayer-Mokler A – PersonEntity: Name: NameFull: Hilf N – PersonEntity: Name: NameFull: Krishna D – PersonEntity: Name: NameFull: Walter S – PersonEntity: Name: NameFull: Tsimberidou AM – PersonEntity: Name: NameFull: Britten CM IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 07 Text: 2024 Jul 22 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 12 – Type: issue Value: 7 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
